Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on Boku

(Sharecast News) - Analysts at Canaccord Genuity initiated coverage on mobile payments firm Boku with a 'buy' rating and 271.0p target price on Monday, stating the group was "owning the rails in a wallet-first world". Canaccord Genuity said Boku has achieved "the rarest of occurrences", having out-executed larger competitors and out-positioned incumbent card processors in the global pivot to local payment methods.

By 2028, roughly 60% of cross-border e-commerce was expected to transact via LPMs such as e-wallets and real-time payments, with Boku sitting "at the heart of this shift", offering global merchants such as Amazon and Google access to an increasingly fragmented patchwork of domestic payment schemes.

"Revenue momentum is building with other LPM revenue increasing from $1.6m in H122 to $14.1m in H124. Management has guided to 20%+ compound revenue growth over the medium term," said Canaccord Genuity, which added that Boku was "a direct beneficiary of the structural shift in global payments" from cash and cards towards mobile-centric, digital payments.

The Canadian bank said "Boku's big idea" was to leverage a decade of integration and commercial relationships from direct carrier billing and redeploy to other LPMs, noting that it has now built a global platform of more than 250 LPMs and over 100 merchants, underpinned by infrastructure and regulatory scale across 74 markets.

"Boku has strong structural drivers, a defensible moat, impressive profitability (FY24: 31.6% adj EBITDA margin), and appears primed to benefit from operating leverage as volumes scale," added Canaccord.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.